Aziyo Biologics Inc. (AZYO) News

Aziyo Biologics Inc. (AZYO): $1.22

-0.23 (-15.86%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Filter AZYO News Items

AZYO News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

AZYO News Highlights

  • For AZYO, its 30 day story count is now at 5.
  • Over the past 21 days, the trend for AZYO's stories per day has been choppy and unclear. It has oscillated between 1 and 3.
  • The most mentioned tickers in articles about AZYO are LI, RM and MD.

Latest AZYO News From Around the Web

Below are the latest news stories about AZIYO BIOLOGICS INC that investors may wish to consider to help them evaluate AZYO as an investment opportunity.

Aziyo sheds 56% as FDA cites issues in marketing submission for antibacterial product

  • Aziyo Biologics (NASDAQ:AZYO), a biotech focused on regenerative medical products, lost ~56% premarket Monday after announcing that the FDA noted deficiencies in its marketing application for CanGaroo RM Antibacterial Envelope.
  • The issue relates to the 510(k) premarket notification the company sought from the FDA in April 2022 for CanGaroo RM, which is designed to cut infection risk following the surgical implantation of an electronic device.
  • Regarding the filing, the FDA has sent a “Not Substantially Equivalent determination,” highlighting the iss...

    Seeking Alpha | March 20, 2023

ACER's Stock Down on Failure of Phase II Study, Cash Updates

ACER announces the failure of its phase IIa study of ACER-801 to treat vasomotor symptoms associated with menopause, along with its extinguishing cash runway. Stock down.

Yahoo | March 20, 2023

Aziyo Biologics Provides Update on FDA Submission for CanGaroo® RM Antibacterial Envelope

SILVER SPRING, Md., March 20, 2023 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (Nasdaq: AZYO), a company that develops and commercializes biologic products to improve compatibility between medical devices and the patients who need them, provides an update on its submission to the U.S. Food and Drug Administration (FDA) for the CanGaroo® RM Antibacterial Envelope, the Company’s next-generation biomaterial envelope. The device is intended to securely hold a cardiac implantable electronic device or n

Yahoo | March 20, 2023

Aziyo Biologics to Report Fourth Quarter and Full Year 2022 Financial Results on Wednesday, March 22, 2023

SILVER SPRING, Md., March 15, 2023 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (Nasdaq: AZYO) (“Aziyo”), a company that develops and commercializes biologic products to improve compatibility between medical devices and the patients who need them, today announced that it will release its fourth quarter and full year 2022 financial results after market close on Wednesday, March 22, 2023. Members of the Company’s management team will host a conference call and webcast with accompanying slides startin

Yahoo | March 15, 2023

Aziyo Biologics to Present at the Cowen 43rd Annual Health Care Conference

SILVER SPRING, Md., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (Nasdaq: AZYO) (“Aziyo”), a company that develops and commercializes biologic products to improve compatibility between medical devices and the patients who need them, today announced that Dr. Randy Mills, President and Chief Executive Officer, and Matt Ferguson, Chief Financial Officer, will present at the Cowen 43rd Annual Health Care Conference. The presentation will take place at the Boston Marriott Copley Place on M

Yahoo | February 27, 2023

SWK Holdings Provides Portfolio Update Highlighting Recent Achievements

SWK Holdings Corporation (Nasdaq: SWKH) ("SWK" or the "Company"), a life science-focused specialty finance company catering to small- and mid-sized commercial-stage companies, today provided an update on its team, portfolio, as well as the progress and achievements of its borrower partners.

Yahoo | January 31, 2023

Aziyo Biologics, Inc. (AZYO) Upgraded to Buy: Here's What You Should Know

Aziyo Biologics, Inc. (AZYO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Yahoo | January 26, 2023

Are Medical Stocks Lagging Bionano Genomics (BNGO) This Year?

Here is how Bionano Genomics, Inc. (BNGO) and Aziyo Biologics, Inc. (AZYO) have performed compared to their sector so far this year.

Yahoo | January 26, 2023

Investors in Aziyo Biologics (NASDAQ:AZYO) have unfortunately lost 38% over the last year

Investors can approximate the average market return by buying an index fund. But if you buy individual stocks, you can...

Yahoo | January 21, 2023

Aziyo Biologics Announces Record Annual Net Sales in Preliminary (Unaudited) Fourth Quarter and Full Year 2022 Topline Results

SILVER SPRING, Md., Jan. 09, 2023 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (Nasdaq: AZYO) (“Aziyo”), a biologics company with a portfolio of regenerative products aimed at improving compatibility between medical devices and the patients they treat, today announced preliminary (unaudited) net sales results for its fourth quarter and full year ended December 31, 2022. Preliminary Fourth Quarter and Full Year 2022 Net Sales Results Anticipate fourth quarter 2022 net sales of approximately $12.5-$1

Yahoo | January 9, 2023


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.6151 seconds.